We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

16 hedge funds and large institutions have $1.67M invested in Evoke Pharma in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

7% more funds holding

Funds holding: 15 → 16 (+1)

0.05% less ownership

Funds ownership: 3.11% → 3.05% (-0.05%)

14% less capital invested

Capital invested by funds: $1.93M → $1.67M (-$262K)

Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$11.4K
2
Citadel Advisors
Citadel Advisors
Florida
+$5.98K
3
State Street
State Street
Massachusetts
+$5.35K
4
Bank of America
Bank of America
North Carolina
+$36
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$36

Top Sellers

Rank Fund Capital Flow
1
ACM
Altium Capital Management
New York
-$16.3K
2
Goldman Sachs
Goldman Sachs
New York
-$8.22K
3
Millennium Management
Millennium Management
New York
-$6.63K
4
Wells Fargo
Wells Fargo
California
-$40
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
AIGH Capital Management
Maryland
$448K – – –
BL
2
Bleichroeder LP
New York
$436K – – –
ACM
3
Altium Capital Management
New York
$366K -$16.3K -2,709 -4%
NCM
4
Nantahala Capital Management
Connecticut
$357K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$26.3K +$11.4K +1,886 +84%
Vanguard Group
6
Vanguard Group
Pennsylvania
$15.8K – – –
Citadel Advisors
7
Citadel Advisors
Florida
$6.3K +$5.98K +993 New
State Street
8
State Street
Massachusetts
$5.64K +$5.35K +888 New
TRCT
9
Tower Research Capital (TRC)
New York
$3.96K +$36 +6 +1%
BlackRock
10
BlackRock
New York
$774 – – –
UBS Group
11
UBS Group
Switzerland
$586 – – –
Morgan Stanley
12
Morgan Stanley
New York
$198 – – –
NA
13
NewEdge Advisors
Louisiana
$110 – – –
Fidelity Investments
14
Fidelity Investments
Massachusetts
$38 +$36 +6 New
Bank of America
15
Bank of America
North Carolina
$37 +$36 +6 New
Goldman Sachs
16
Goldman Sachs
New York
– -$8.22K -1,123 Closed
Millennium Management
17
Millennium Management
New York
– -$6.63K -906 Closed
Wells Fargo
18
Wells Fargo
California
– -$40 -6 Closed

EVOK Hedge Fund Activity: Q2 2024 in Review

16 of the 6,929 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q2 2024, worth a combined $1.67M — down 14% from $1.93M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new EVOK positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $11.4K. The largest seller was Altium Capital Management, cutting an estimated $16.3K.

  • 16 institutional investors held Evoke Pharma (EVOK) as of Q2 2024, up from 15 in Q1 2024.
  • Funds reported $1.67M of Evoke Pharma stock for Q2 2024, down 14% quarter-over-quarter.
  • 4 funds opened new Evoke Pharma positions in Q2 2024 and 3 closed out, a net change of +1 holder.
  • The largest Evoke Pharma buyer in Q2 2024 was Geode Capital Management, an estimated $11.4K added.
  • The largest Evoke Pharma seller in Q2 2024 was Altium Capital Management, an estimated $16.3K sold.

Based on aggregated 13F filings for Q2 2024.